Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 ...

Actress, singer and health advocate Jamie-Lynn Sigler has been entertaining audiences since the age of seven, getting her ...

The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Morgan Stanley (NYSE:MS) initiated coverage on Novartis (SIX:NOVN:SW) (NYSE: NVS) with an Underweight rating and set a price ...

Adults with relapsing MS rated the Sensoready pen, an autoinjector used to self-administer Kesimpta, for ease of use and ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug Entresto and newer multiple sclerosis drug Kesimpta exceeded forecasts.

Novartis on Friday posted quarterly adjusted net income well above analyst estimates on forecast-beating sales of established ...

Initially launching in Germany, the app will soon be available in the UK, Australia, Canada, and other markets.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Remibrutinib is under clinical development by Novartis and currently in Phase III for Relapsing Remitting Multiple Sclerosis (RRMS). According to GlobalData, Phase III drugs for Relapsing Remitting ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...